Difference between revisions of "Lee:JC"

From OpenWetWare
(Monthly proteasome meeting schedule)
Line 71: Line 71:
==Past papers==
==Past papers==
# Pinilla-Macua I, Casado FJ, Pastor-Anglada M. Structural determinants for rCNT2 sorting to the plasma membrane of polarized and non-polarized cells. Biochem J. 2012 Mar 15;442(3):517-25. doi: 10.1042/BJ20110605.

Revision as of 10:42, 9 January 2013


Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 

Lee Lab Research Meeting

  • 4 - 5:30 pm, every other Monday, BPC Rm 387

Lee Lab JC

  • 4-5:30 pm, every other Monday, BPC Rm 387
Date Presenter
1/7/13 Nilay
1/21/13 Youngran
2/4/13 KB
2/18/13 Lin
3/4/13 Nilay
3/18/13 Youngran
4/1/13 KB
4/15/13 Lin
4/29/13 Nilay
5/13/13 Youngran
5/27/13 KB

Monthly proteasome meeting schedule

  • 4 - 5:30 pm, Last Weds, BPC Rm 387
Date Presenter/discussion leader
01/30/13 Kim
02/27/13 Ji-Eun
03/27/13 Lin
04/24/13 Zach
05/29/13 Do-Min

Suggested future papers

  1. Eloranta JJ, Hiller C, Juttner M, Kullak-Ublick GA. The SLCO1A2 Gene, Encoding the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2), is Transactivated by the Vitamin D Receptor (VDR). Mol Pharmacol. 2012 Apr 3. [Epub ahead of print]
  2. Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 2011 Jan 27;117(4):1270-9. Epub 2010 Nov 24.
  3. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008 Sep 1;112(5):2013-6. pmid=18566324
  4. Kotamraju S, Matalon S, Matsunaga T, Shang T, Hickman-Davis JM, Kalyanaraman B. Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med. 2006 Mar 15;40(6):1034-44. pmid=16540399
  5. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.Blood. 2009 Jul 30;114(5):1046-52. pmid=19436050
  6. Hussong SA, Roehrich H, Kapphahn RJ, Maldonado M, Pardue MT, Ferrington DA. A Novel Role for Immunoproteasome in Retinal Function. Invest Ophthalmol Vis Sci. 2010 pmid=20881299
  7. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, Kuckelkorn U, Aktas O, Kloetzel PM, Krüger E. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell. 2010 Aug 20;142(4):613-24. (pmid=20723761)
  8. Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. Eur J Immunol. 2011 Jan;41(1):39-46. (PMID=21182075)
  9. Steffen J, Seeger M, Koch A, Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 2010 Oct 8;40(1):147-58.

Past papers


  1. Pinilla-Macua I, Casado FJ, Pastor-Anglada M. Structural determinants for rCNT2 sorting to the plasma membrane of polarized and non-polarized cells. Biochem J. 2012 Mar 15;442(3):517-25. doi: 10.1042/BJ20110605.


  1. Fang C, Dean J, Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. (pmid=17909007) (1/17/12 SH)
  2. Screen M, Britton M, Downey SL, Verdoes M, Voges MJ, Blom AE, Geurink PP, Risseeuw MD, Florea BI, van der Linden WA, Pletnev AA, Overkleeft HS, Kisselev AF. Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem. 2010 Dec 17;285(51):40125-34. Epub 2010 Oct 11. (1/31/12 DM)
  3. Kasuya K, Tsuchida A, Nagakawa Y, Suzuki M, Abe Y, Itoi T, Serizawa H, Nagao T, Shimazu M, Aoki T. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer ONCOLOGY REPORTS 26: 1399-1406, 2011 (2/14/12 NT)
  4. Heink S, Fricke B, Ludwig D, Kloetzel PM, Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. PMID:16423992 (2/28/12 JP)
  5. Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. Epub 2012 Jan 10. (3/13/12 KBj)
  6. Xu H, Fu J, Ha SW, Ju D, Zheng J, Li L, Xie Y. The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes. Biochim Biophys Acta. 2012 Apr;1823(4):818-25. Epub 2012 Jan 20. (3/27/12 LA)
  7. Jin L, Kikuchi R, Saji T, Kusuhara H, Sugiyama Y. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 α/β and DNA methylation.J Pharmacol Exp Ther. 2012 Mar;340(3):648-55. Epub 2011 Dec 7. (4/10/12 SH)
  8. Barretina J et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28;483(7391):603-7. (5/8/12 W)
  9. Degorter MK, Ho RH, Leake BF, Tirona RG, Kim RB. Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm. 2012 Apr 2;9(4):986-95. Epub 2012 Mar 6. (PMID: 22352740) (5/33/12, NT)
  10. Fellerhoff B, Gu S, Laumbacher B, Nerlich AG, Weiss EH, Glas J, Kopp R, Johnson JP, Wank R. The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Res. 2011 Dec 1;71(23):7145-54. Epub 2011 Oct 28. (PMID: 22037870) (6/5/12, JP)
  11. Errasti-Murugarren E, Molina-Arcas M, Casado FJ, Pastor-Anglada M. A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB J. 2009 Jan;23(1):172-82. (PMID=18827020) (6/19/12, KBj)
  12. Wang Z, Sun Y. Identification and characterization of two splicing variants of human Noxa. Anticancer Res. 2008 May-Jun;28(3A):1667-74. (PMID=18630524) (7/2/12, YL)
  13. Higashimura Y, Nakajima Y, Yamaji R, Harada N, Shibasaki F, Nakano Y, Inui H. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. Arch Biochem Biophys. 2011 May 1;509(1):1-8. (PMID=21338575) (7/31/12 SHH)
  14. Errasti-Murugarren E, Casado FJ, Pastor-Anglada M. Different N-terminal motifs determine plasma membrane targeting of the human concentrative nucleoside transporter 3 in polarized and nonpolarized cells. Mol Pharmacol. 2010 Nov;78(5):795-803. (PMID=20643903 8/14/12 NT)
  15. Hammerman PS et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun;1(1):78-89. (PMID=22328973, 8/28/12 YRL)
  16. Heink S, Ludwig D, Kloetzel PM, Krüger E. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9241-6. (PMID: 15944226 9/10/12 KBj)
  17. Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, Bruzzese FJ, Barrett C, Liu JX, Soucy TA, Sappal DS, Bump N, Olhava EJ, Fleming P, Dick LR, Tsu C, Sintchak MD, Blank JL. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J. 2010 Sep 15;430(3):461-76. (9/24/12 JP)
  18. Joeris T, Schmidt N, Ermert D, Krienke P, Visekruna A, Kuckelkorn U, Kaufmann SH, Steinhoff U. The proteasome system in infection: impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes. PLoS One. 2012;7(6):e39827. (10/9/12 LA)
  19. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW.Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004 Sep;11(9):1028-37. PMID: 15131592 (10/22/12 NT)
  20. Yang K, Kim JH, Kim HJ, Park IS, Kim IY, Yang BS. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. J Biol Chem. 2005 Nov 25;280(47):39058-66. (11/5/12 YRL)
  21. Mishto M, Santoro A, Bellavista E, Sessions R, Textoris-Taube K, Dal Piaz F, Carrard G, Forti K, Salvioli S, Friguet B, Kloetzel PM, Rivett AJ, Franceschi C. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem. 2006 Apr;387(4):417-29. (PMID:16606340) (11/19/12 JP)
  22. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X, Chung DC. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem. 2006;281(20):13957-63. (12/3/12, KBj)
  23. Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ. Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo. ACS Chem Biol. 2012 Dec 11. (12/17/11, LA)


  1. Unsworth H, Raguz S, Edwards HJ, Higgins CF, Yagüe E. mRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum. FASEB J. 2010 Sep;24(9):3370-80. (1/6/11 W)
  2. Weaver YM, Hagenbuch B. Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates. J Membr Biol. 2010 Aug;236(3):279-90. (2/14/11 NT)
  3. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science. 2010 Feb 19;327(5968):996-1000. (2/28/11 ERJ)
  4. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010 Aug;24(8):1506-12. (3/14/11 KHK)
  5. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011 Mar 1. (3/28/11 DHK)
  6. Meyer Zu Schwabedissen HE, Ware JA, Tirona RG, Kim RB. Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.Mol Pharm. 2009 Nov-Dec;6(6):1790-7. (4/18/11 NT)
  7. Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia. 2009 Jun;23(6):1098-105. (5/2/11 KHK)
  8. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. (PMID: 20937868) (6/6/11 ERJ)
  9. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009 May 14;52(9):3028-38. (PMID: 19348473) (6/20/11 WL)
  10. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics. 2011 Mar;21(3):103-14. (7/11/11 MA)
  11. Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, Yewdell JW. Unexpected Role for the Immunoproteasome Subunit LMP2 in Antiviral Humoral and Innate Immune Responses. J Immunol. 2010 Apr 15;184(8):4115-22. (PMID: 20228196) (8/22/11 ERJ)
  12. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G271-8. (9/19/11 NT)
  13. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol. 2009 Mar;296(3):C570-82. (10/3/11 JF)
  14. Martinez-Becerra P, Briz O, Romero MR, Macias RI, Perez MJ, Sancho-Mateo C, Lostao MP, Fernandez-Abalos JM, Marin JJ. Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol Pharmacol. 2011 Mar;79(3):596-607. (10/25/11 SHH)
  15. Mandery K, Sticht H, Bujok K, Schmidt I, Fahrmayr C, Balk B, Fromm MF, Glaeser H. Functional and structural relevance of conserved positively charged lysine residues in organic anion transporting polypeptide 1B3. Mol Pharmacol. 2011 Sep;80(3):400-6. (10/31/11 DM)
  16. Koslowski M, Luxemburger U, Türeci O, Sahin U. Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α. Oncogene. 2011 Feb 17;30(7):876-82. Epub 2010 Nov 1.
  17. Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, Lee CA. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metab Dispos. 2011 Nov;39(11):2093-102. Epub 2011 Aug 17.


  1. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009 Oct 15;114(16):3439-47. (pmid=19671918)
  2. Deborah J. Kuhn,1 Sally A. Hunsucker,1 Qing Chen,2 Peter M. Voorhees,2 Marian Orlowski,3 Robert Z. Orlowski1. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.Blood. 2009 May 7;113(19):4667-76. (pmid=19050304)
  3. Giada Bianchi,Laura Oliva,Paolo Cascio,5 Niccolo Pengo,Francesca Fontana, Fulvia Cerruti, Andrea Orsi,Elena Pasqualetto, Alexandre Mezghrani, Valeria Calbi, Giovanni Palladini, Nicola Giuliani, Kenneth C. Anderson,Roberto Sitia,and Simone Cenci. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26;113(13):3040-9 : 3040-3049.(pmid=19164601)
  4. Hideo Ohtsuka1, Takaaki Abe2,3, Tohru Onogawa1, Noriko Kondo1, Takeaki Sato1, Hiroshi Oshio1, Hiroya Mizutamari4, Tsuyoshi Mikkaichi3, Masaya Oikawa1, Toshiki Rikiyama1, Yu Katayose1, and Michiaki Unno1. Farnesoid X receptor, hepatocyte nuclear factors 1a and 3b are essential for transcriptional activation of the liver-specific organic anion. J Gastroenterol. 2006 Apr;41(4) : 369-77. (pmid=16741617)
  5. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. (pmid=18502982)
  6. Muñoz MJ, Pérez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ, Bird G, Bentley D, Bertrand E, Kornblihtt AR. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell. 2009;137(4):708-20. (pmid=19450518)
  7. Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol. 2004 Feb;40(2):212-8. (pmid=14739090)
  8. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007 Mar 2;354(1):154-9. (pmid=17214962)
  9. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008 Jan 1;103(1):270-83. (pmid=17516511)
  10. Imai S, Kikuchi R, Kusuhara H, Yagi S, Shiota K, Sugiyama Y. Analysis of DNA methylation and histone modification profiles of liver-specific transporters. Mol Pharmacol. 2009 Mar;75(3):568-576 (8/3/10)
  11. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells.Mol Cancer. 2010 May 18;9: 110(8/10/10)
  12. Kim SN, Kim NH, Lee W, Seo DW, Kim YK. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res. 2009 May;7(5):735-44 pmid=19435809 (9/16/10)
  13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009 Mar 15;69(6):2305-13 pmid=19244107 (9/23/10)
  14. Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, and Tamai I. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010 Oct; 122(4) 180-5(10/7/10)
  15. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010 Aug 2; 120(8) 2942-52. doi:10.1172/JCI42168 pmid:20644253
  16. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB.Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 2008 Nov 15;68(22):9338-47.PMID: 19010908 (10/28/10)
  17. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW.Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004 Sep;11(9):1028-37. PMID: 15131592 (11/11/10)
  18. Guo Q, Chen Y, Wu Y. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1. Tumori. 2009 Nov-Dec;95(6):796-803. PMID: 20210246 (11/18/10)


  1. Fang C, Dean J, Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. (pmid=17909007)
  2. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, Ping P. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics. 2009 Feb;8(2):302-15. (pmid=18931337)
  3. Gui C, Hagenbuch B. Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transportBiochemistry. 2008 Sep 2;47(35):9090-7. (pmid=18690707)
  4. Iorns E, Lord CJ, Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009 Jan 1;417(1):361-70. (pmid=18976239)
  5. Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol. 2009 Apr;156(1):172-82. (pmid=19220323)
  6. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007 Oct;12(4):355-66. (pmid=17936560)
  7. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, Cohen L, Danon T, Perzov N, Alon U. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008 Dec 5;322(5907):1511-6. (pmid=19023046)
  8. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000 Apr 15;60(8):2090-4. (pmid=10786665)
  9. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.Cancer Res. 2000 Apr 15;60(8):2090-4. (pmid=9751059)
  10. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):297-300.(pmid=9751060)
  11. Kravtsova-Ivantsiv Y, Cohen S, Ciechanover A. Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor. Mol Cell. 2009 Feb 27;33(4):496-504. (pmid=19250910)
  12. Shah K, Liu Y, Deirmengian C, Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70. (pmid=9108016)
  13. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.Cancer Cell. 2007 Feb;11(2):119-32. (pmid=17292824)
  14. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998 Oct 29;395(6705):917-21. (pmid=9804427)
  15. Yang Z, Gagarin D, St Laurent G 3rd, Hammell N, Toma I, Hu CA, Iwasa A, McCaffrey TA. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1213-9. (pmid=19443843)
  16. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.Nature. 2004 Sep 23;431(7007):461-6. Epub 2004 Aug 25. (pmid=15329734)
  17. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.Hepatology. 2008 Nov;48(5):1632-43. (pmid=18972444)
  18. Nakagawa H, Tamura A, Wakabayashi K, Hoshijima K, Komada M, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem J. 2008 May 1;411(3):623-31.(pmid=18237272)
  19. Kimura Y, Yashiroda H, Kudo T, Koitabashi S, Murata S, Kakizuka A, Tanaka K. An inhibitor of a deubiquitinating enzyme regulates ubiquitin homeostasis.Cell. 2009 May 1;137(3):549-59. (pmid=19410548)
  20. Yi F, Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol. 2008 Oct 17;3(10):645-54. Epub 2008 Sep 12.(pmid=18785742)
  21. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008 Sep 15;112(6):2489-99. (pmid=18565852)
  22. Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res. 2008 Aug 15;14(16):5116-23. (pmid=18698029)
  23. Voortman J, Checińska A, Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer. 2007 Nov 17;6:73. (pmid=18021420)
  24. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol. 2009 Jul 1;183(1):66-74. Epub 2009 Jun 17. (pmid=19535631)
  25. Shabek N, Herman-Bachinsky Y, Ciechanover A. Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11907-12. (pmid=19581590)
  26. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002 Jun 15;62(12):3387-94. (pmid=12067980)
  27. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7. (pmid=12527911)
  28. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. (pmid=17591945)
  29. Khan MA, Oubrahim H, Stadtman ER. Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11560-5. Epub 2004 Jul 29. (pmid=15284441)
  30. Xu M, Skaug B, Zeng W, Chen ZJ. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell. 2009 Oct 23;36(2):302-14. (pmid=19854138)
  31. Comerford KM, Cummins EP, Taylor CT. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004 Dec 15;64(24):9057-61. (pmid=15604272)